SCHEMBL5361587

SCHEMBL5361587

CC(C)(C)c1cc(C=C2C(=O)Nc3ccc(CCCl)cc32)ccc1O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 5/20 0.53
EGFR P00533 3/20 0.53
IGF1R P08069 1/20 0.51
LRRK2 Q5S007 4/20 0.49
PLK4 O00444 1/20 0.49
NOX4 Q9NPH5 2/20 0.46
PSEN1 P49768 2/20 0.46
PSEN2 P49810 2/20 0.46
APH1B Q8WW43 2/20 0.46
NCSTN Q92542 2/20 0.46
APH1A Q96BI3 2/20 0.46
PSENEN Q9NZ42 2/20 0.46
APP P05067 1/20 0.43
MAPT P10636 1/20 0.43
SNCA P37840 1/20 0.43
RAF1 P04049 1/20 0.41
GSK3B P49841 1/20 0.41
PDGFRB P09619 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5362863 0.89 ERBB2 (0.65) ERBB2EGFRIGF1RLRRK2PLK4
SCHEMBL5367874 0.86 LRRK2 (0.54) ERBB2EGFRLRRK2PLK4NOX4
SCHEMBL5364127 0.86 ERBB2 (0.73) ERBB2EGFRIGF1RLRRK2PLK4
SCHEMBL5366594 0.86 ERBB2 (0.57) ERBB2EGFRIGF1RLRRK2PLK4
SCHEMBL5364476 0.86 ERBB2 (0.57) ERBB2EGFRIGF1RLRRK2PLK4
SCHEMBL5367313 0.85 LRRK2 (0.56) ERBB2EGFRIGF1RLRRK2PLK4
SCHEMBL5370082 0.84 LRRK2 (0.70) EGFRLRRK2PLK4NOX4PSEN1
SCHEMBL7139546 0.84 PSEN1 (0.49) ERBB2EGFRLRRK2PSEN1PSEN2
SCHEMBL5364965 0.83 ERBB2 (0.63) ERBB2EGFRIGF1RLRRK2PLK4
SCHEMBL5370145 0.82 ERBB2 (0.56) ERBB2EGFRIGF1RLRRK2PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERBB2 19/4885EGFR 286/4885IGF1R 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.